Hyperkalaemia-related reduction of RAASi treatment associates with more subsequent inpatient care.

ABSTRACT:

Background

Hyperkalaemia is a barrier to achieving optimal, guideline-directed treatment with renin-angiotensin-aldosterone system inhibitors (RAASis) in patients with chronic kidney disease (CKD) and/or heart failure (HF). This study describes the association between hyperkalaemia-related RAASi treatment reduction and the number of hospitalized days in patients with CKD and/or HF in Sweden and Japan.

Methods

Using data from health registers and hospital medical records, patients with CKD and/or HF currently receiving RAASis who experienced an index hyperkalaemia episode were identified and categorized as having maintained or reduced RAASi treatment post-index; propensity score matching (1:1) was applied to balance the groups in terms of baseline characteristics. Changes in

SUBMITTER: Svensson MK 

PROVIDER: S-EPMC11334062 | biostudies-literature | 2024 Jul

REPOSITORIES: biostudies-literature